Chordate Medical Holding AB Stock

Equities

CMH

SE0009495559

Advanced Medical Equipment & Technology

Delayed Nasdaq Stockholm 09:03:46 2024-04-29 am EDT 5-day change 1st Jan Change
0.0538 SEK -3.58% Intraday chart for Chordate Medical Holding AB -3.58% -66.46%
Sales 2022 109K 9.93K Sales 2023 1.75M 160K Capitalization 37.28M 3.41M
Net income 2022 -27M -2.47M Net income 2023 -29M -2.65M EV / Sales 2022 723 x
Net cash position 2022 3.68M 336K Net cash position 2023 8.46M 774K EV / Sales 2023 16.5 x
P/E ratio 2022
-2.89 x
P/E ratio 2023
-1.23 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 36.96%
More Fundamentals * Assessed data
Dynamic Chart
Chordate Medical Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chordate Medical Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Chordate Medical Gains EU Patent for Chronic Migraine Treatment MT
Chordate Medical Holding AB Announces the European Patent Office Grants New Patent CI
Chordate Medical Holding AB Signs Agreement with German Clinic for the Ozilia Treatment for Chronic Migraine CI
Chordate Medical Completes Training of Clinic Staff and Assists in Initiation of Treatment for First Three Patients at the Private Clinic in Hamburg CI
Chordate Medical Holding AB Announces First Patients Included in the Post-Market Study PM010 CI
Chordate Medical Holding AB Announces First Patient Included in the Company's Open Pilot Study PM009 CI
Chordate Medical Holding AB Receives First Installation of the Ozilia Migraine Treatment at a Private Clinic in Hamburg CI
Chordate Medical Holding AB Announces Post-Market Study of Chordate's Ozilia® Migraine Treatment Has Commenced in Four Different Markets CI
Chordate Medical Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chordate Medical Trademarks Migraine Treatment Ozilia in EU MT
Chordate Medical Receives Registration of the Tradark Ozilia CI
Chordate Medical Holding AB Introduces New Trademark for Migraine Treatment: Ozilia? - Migraine Relief CI
Chordate Medical Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news
1 day-3.58%
1 week-3.58%
Current month-20.53%
1 month-8.50%
3 months-61.79%
6 months-78.17%
Current year-66.46%
More quotes
1 week
0.05
Extreme 0.0524
0.06
1 month
0.05
Extreme 0.051
0.07
Current year
0.05
Extreme 0.048
0.24
1 year
0.05
Extreme 0.048
0.50
3 years
0.05
Extreme 0.048
5.56
5 years
0.05
Extreme 0.048
5.56
10 years
0.05
Extreme 0.048
14.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 14-10-31
Director of Finance/CFO 56 17-10-01
Chief Tech/Sci/R&D Officer 68 11-12-31
Members of the board TitleAgeSince
Director/Board Member 69 14-05-31
Director/Board Member 61 17-03-31
Chief Executive Officer 63 14-10-31
More insiders
Date Price Change Volume
24-04-29 0.0538 -3.58% 395 392
24-04-26 0.0558 -2.79% 1,084,519
24-04-25 0.0574 -2.05% 595,813
24-04-24 0.0586 -1.68% 467,470
24-04-23 0.0596 +6.81% 282,114

Delayed Quote Nasdaq Stockholm, April 29, 2024 at 09:03 am EDT

More quotes
Chordate Medical Holding AB (publ) is a medical technology company based in Sweden. The Company develops treatment method through nerve stimulation for chronic nasal congestion. The Company’s headquartered is located in Kista, Sweden.
Calendar
More about the company